{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T14:33:15Z","timestamp":1772029995757,"version":"3.50.1"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81873761"],"award-info":[{"award-number":["81873761"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010270","name":"Capital Health Research and Development of Special Fund","doi-asserted-by":"publisher","award":["2022-1-2152"],"award-info":[{"award-number":["2022-1-2152"]}],"id":[{"id":"10.13039\/501100010270","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.blre.2022.100965","type":"journal-article","created":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T17:26:12Z","timestamp":1650734772000},"page":"100965","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["One arrow for two targets: potential co-treatment regimens for lymphoma and HIV"],"prefix":"10.1016","volume":"55","author":[{"given":"Xue","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuqun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.blre.2022.100965_bb0005","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrclinonc.2014.31","article-title":"Diagnosis and management of lymphomas and other cancers in HIV-infected patients","volume":"11","author":"Carbone","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2022.100965_bb0010","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1055-9965.EPI-13-0865","article-title":"Prevalence of HIV infection among U.S. Hodgkin lymphoma cases","volume":"23","author":"Shiels","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"12","key":"10.1016\/j.blre.2022.100965_bb0015","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/S1470-2045(09)70282-7","article-title":"Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study","volume":"10","author":"Guiguet","year":"2009","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.blre.2022.100965_bb0020","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5045\/br.2019.54.3.181","article-title":"HIV\/AIDS-related lymphoma: perspective from a regional cancer center in India","volume":"54","author":"Rudresha","year":"2019","journal-title":"Blood Res"},{"issue":"6","key":"10.1016\/j.blre.2022.100965_bb0025","first-page":"1","article-title":"British HIV Association guidelines for HIV-associated malignancies 2014","volume":"15","author":"Bower","year":"2008","journal-title":"HIV Med"},{"issue":"17","key":"10.1016\/j.blre.2022.100965_bb0030","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1182\/blood-2018-01-791400","article-title":"Optimizing treatment of HIV-associated lymphoma","volume":"134","author":"Noy","year":"2019","journal-title":"Blood"},{"issue":"7751","key":"10.1016\/j.blre.2022.100965_bb0035","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","article-title":"HIV-1 remission following CCR5\u039432\/\u039432 haematopoietic stem-cell transplantation","volume":"568","author":"Gupta","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.blre.2022.100965_bb0040","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3018(20)30069-2","article-title":"Evidence for HIV-1 cure after CCR5\u039432\/\u039432 allogeneic haemopoietic stem-cell transplantation 30\u00a0months post analytical treatment interruption: a case report","volume":"7","author":"Gupta","year":"2020","journal-title":"The Lancet HIV"},{"issue":"5","key":"10.1016\/j.blre.2022.100965_bb0045","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.20.01447","article-title":"Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2022.100965_bb0050","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.stem.2019.04.010","article-title":"Lessons from London and Berlin: Designing A Scalable Gene Therapy Approach for HIV Cure","volume":"24","author":"Peterson","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.blre.2022.100965_bb0055","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1146\/annurev.immunol.17.1.657","article-title":"Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease","volume":"17","author":"Berger","year":"1999","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"10.1016\/j.blre.2022.100965_bb0060","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/COH.0b013e328356f6f2","article-title":"Correlation of coreceptor usage and disease progression","volume":"7","author":"Verhofstede","year":"2012","journal-title":"Curr Opin HIV AIDS"},{"issue":"3","key":"10.1016\/j.blre.2022.100965_bb0065","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0092-8674(00)80110-5","article-title":"Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection","volume":"86","author":"Liu","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.blre.2022.100965_bb0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atg.2013.05.004","article-title":"CC chemokine receptor type five (CCR5): An emerging target for the control of HIV infection","volume":"2","author":"Barmania","year":"2013","journal-title":"Applied & translational genomics"},{"issue":"9079","key":"10.1016\/j.blre.2022.100965_bb0075","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(05)63552-0","article-title":"CCR5-delta 32 gene deletion in HIV-1 infected patients","volume":"350","author":"Michael","year":"1997","journal-title":"Lancet (London, England)"},{"issue":"36","key":"10.1016\/j.blre.2022.100965_bb0080","doi-asserted-by":"crossref","first-page":"14642","DOI":"10.1021\/ja301099s","article-title":"Cell surface assembly of HIV gp41 six-helix bundles for facile, quantitative measurements of hetero-oligomeric interactions","volume":"134","author":"Hu","year":"2012","journal-title":"J Am Chem Soc"},{"issue":"6686","key":"10.1016\/j.blre.2022.100965_bb0085","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/31405","article-title":"Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody","volume":"393","author":"Kwong","year":"1998","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.blre.2022.100965_bb0090","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.tim.2019.06.002","article-title":"Molecular Mechanism of HIV-1 Entry","volume":"27","author":"Chen","year":"2019","journal-title":"Trends Microbiol"},{"issue":"7","key":"10.1016\/j.blre.2022.100965_bb0095","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.296.7.815","article-title":"Biology of CCR5 and its role in HIV infection and treatment","volume":"296","author":"Lederman","year":"2006","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.blre.2022.100965_bb0100","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2010-09-309591","article-title":"Evidence for the Cure of HIV Infection by CCR532\/32 Stem Cell Transplantation","volume":"117","author":"Allers","year":"2011","journal-title":"Blood"},{"issue":"5290","key":"10.1016\/j.blre.2022.100965_bb0105","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1126\/science.274.5290.1069.a","article-title":"Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene","volume":"274","author":"Dean","year":"1996","journal-title":"Science"},{"issue":"6593","key":"10.1016\/j.blre.2022.100965_bb0110","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/382722a0","article-title":"Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene","volume":"382","author":"Samson","year":"1996","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.blre.2022.100965_bb0115","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nbt.2868","article-title":"HIV eradication\u2013from Berlin to Boston","volume":"32","author":"Cannon","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"26","key":"10.1016\/j.blre.2022.100965_bb0120","first-page":"06","article-title":"Hopes of HIV cure in \u2018Boston patients\u2019 dashed","volume":"5","author":"Hayden","year":"2013","journal-title":"Nature News"},{"issue":"7","key":"10.1016\/j.blre.2022.100965_bb0130","doi-asserted-by":"crossref","DOI":"10.1172\/JCI144486","article-title":"CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication","volume":"131","author":"Tebas","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2022.100965_bb0135","doi-asserted-by":"crossref","first-page":"16067","DOI":"10.1038\/mtm.2016.67","article-title":"Preclinical development and qualification of ZFN-mediated CCR5 disruption in human haematopoietic stem\/progenitor cells","volume":"3","author":"DiGiusto","year":"2016","journal-title":"Molecular Ther Meth Clin Dev"},{"issue":"7","key":"10.1016\/j.blre.2022.100965_bb0140","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nbt1410","article-title":"Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases","volume":"26","author":"Perez","year":"2008","journal-title":"Nat Biotechnol"},{"issue":"13","key":"10.1016\/j.blre.2022.100965_bb0145","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1056\/NEJMoa1817426","article-title":"CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukaemia","volume":"381","author":"Xu","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2022.100965_bb0150","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41577-018-0042-2","article-title":"CAR T cells for infection, autoimmunity and allotransplantation","volume":"18","author":"Maldini","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.blre.2022.100965_bb0155","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S2352-3026(20)30142-3","article-title":"CAR T-cell therapy for cancer and HIV through novel approaches to HIV-associated haematological malignancies","volume":"7","author":"Rust","year":"2020","journal-title":"The Lancet Hematology"},{"issue":"9","key":"10.1016\/j.blre.2022.100965_bb0160","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood.V84.9.2878.2878","article-title":"Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors","volume":"84","author":"Roberts","year":"1994","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2022.100965_bb0165","doi-asserted-by":"crossref","first-page":"6685","DOI":"10.1128\/JVI.00474-15","article-title":"Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity","volume":"89","author":"Liu","year":"2015","journal-title":"J Virol"},{"issue":"504","key":"10.1016\/j.blre.2022.100965_bb0170","doi-asserted-by":"crossref","first-page":"eaav5685","DOI":"10.1126\/scitranslmed.aav5685","article-title":"Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model","volume":"11","author":"Anthony-Gonda","year":"2019","journal-title":"Ence Trans Med"},{"key":"10.1016\/j.blre.2022.100965_bb0175","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3389\/fimmu.2020.00361","article-title":"Advances in Developing CAR T-Cell Therapy for HIV Cure","volume":"11","author":"Qi","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.blre.2022.100965_bb0180","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.cell.2019.10.002","article-title":"Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform","volume":"179","author":"Herzig","year":"2019","journal-title":"Cell"},{"issue":"21","key":"10.1016\/j.blre.2022.100965_bb0185","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1002\/cncr.32411","article-title":"Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma","volume":"125","author":"Abramson","year":"2019","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.blre.2022.100965_bb0190","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150211","article-title":"Broadly neutralizing antibody-derived CAR T cells reduce viral reservoir in individuals infected with HIV-1","volume":"131","author":"Liu","year":"2021","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.blre.2022.100965_bb0195","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"issue":"7077","key":"10.1016\/j.blre.2022.100965_bb0200","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.blre.2022.100965_bb0205","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 Expression is Characteristic of a Subset of Aggressive B-Cell Lymphomas and Virus-Associated Malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.blre.2022.100965_bb0210","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"24","key":"10.1016\/j.blre.2022.100965_bb0215","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2015-12-686550","article-title":"Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas","volume":"127","author":"Georgiou","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2022.100965_bb0220","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","article-title":"PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma","volume":"111","author":"Yamamoto","year":"2008","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.blre.2022.100965_bb0225","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.blre.2022.100965_bb0230","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2022.100965_bb0235","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"7235","key":"10.1016\/j.blre.2022.100965_bb0240","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nature07662","article-title":"Enhancing SIV-specific immunity in vivo by PD-1 blockade","volume":"458","author":"Velu","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.blre.2022.100965_bb0245","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.3389\/fimmu.2018.02339","article-title":"Targeting Immune Checkpoint Molecules to Eliminate Latent HIV","volume":"9","author":"Boyer","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2022.100965_bb0250","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12977-015-0144-x","article-title":"Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options","volume":"12","author":"Velu","year":"2015","journal-title":"Retrovirology"},{"issue":"7109","key":"10.1016\/j.blre.2022.100965_bb0255","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.blre.2022.100965_bb0260","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-065X.2009.00767.x","article-title":"PD-1 signalling in primary T cells","volume":"229","author":"Riley","year":"2009","journal-title":"Immunol Rev"},{"issue":"5","key":"10.1016\/j.blre.2022.100965_bb0265","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/ni.3399","article-title":"Tumour-necrosis factor impairs CD4(+) T cell-mediated immunological control in chronic viral infection","volume":"17","author":"Beyer","year":"2016","journal-title":"Nat Immunol"},{"issue":"7","key":"10.1016\/j.blre.2022.100965_bb0270","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/nm.4113","article-title":"PD-1\u00a0+\u00a0and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals","volume":"22","author":"Banga","year":"2016","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.blre.2022.100965_bb0275","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/hiv.13031","article-title":"HIV DNA reservoir and elevated PD-1 expression of CD4 T-cell subsets particularly persist in the terminal ileum of HIV-positive patients despite cART","volume":"22","author":"Horn","year":"2021","journal-title":"HIV Med"},{"issue":"1","key":"10.1016\/j.blre.2022.100965_bb0280","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41467-019-08798-7","article-title":"PD-1 blockade potentiates HIV latency reversal ex vivo in CD4 T cells from ART-suppressed individuals","volume":"10","author":"Fromentin","year":"2019","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.blre.2022.100965_bb0285","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002097","article-title":"Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma","volume":"9","author":"Lurain","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.blre.2022.100965_bb0290","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4049\/jimmunol.1201108","article-title":"In vivo blockade of the PD-1 receptor suppresses HIV-1 viral loads and improves CD4+ T cell levels in humanized mice","volume":"190","author":"Palmer","year":"2013","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.blre.2022.100965_bb0295","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41571-019-0225-1","article-title":"Genetic alterations and their clinical implications in DLBCL","volume":"16","author":"Miao","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2022.100965_bb0300","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.seminhematol.2015.01.008","article-title":"B-Cell Receptor Signalling in Diffuse Large B-Cell lymphoma","volume":"52","author":"Young","year":"2015","journal-title":"Semin Hematol"},{"issue":"6","key":"10.1016\/j.blre.2022.100965_bb0305","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061396","article-title":"Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies","volume":"12","author":"Efremov","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.blre.2022.100965_bb0310","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1358\/dot.2014.50.4.2133570","article-title":"Ibrutinib for the treatment of chronic lymphocytic leukaemia and mantle cell lymphoma","volume":"50","author":"Mcdermott","year":"2014","journal-title":"Drugs Today"},{"issue":"15","key":"10.1016\/j.blre.2022.100965_bb0315","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"16","key":"10.1016\/j.blre.2022.100965_bb0320","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1097\/QAD.0000000000000442","article-title":"HIV-1 induces B-cell activation and class switch recombination via spleen tyrosine kinase and c-Jun N-terminal kinase pathways","volume":"28","author":"Peris\u00e9-Barrios","year":"2014","journal-title":"AIDS (London, England)"},{"issue":"4","key":"10.1016\/j.blre.2022.100965_bb0325","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood-2004-10-3819","article-title":"c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells","volume":"106","author":"Gururajan","year":"2005","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.blre.2022.100965_bb0330","doi-asserted-by":"crossref","first-page":"13489","DOI":"10.1073\/pnas.1935944100","article-title":"The inhibitory potential of Fc receptor homolog 4 on memory B cells","volume":"100","author":"Ehrhardt","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"10.1016\/j.blre.2022.100965_bb0335","doi-asserted-by":"crossref","first-page":"5870","DOI":"10.1182\/blood-2010-09-310318","article-title":"CD300a is expressed on human B cells, modulates BCR-mediated signalling, and its expression is down-regulated in HIV infection","volume":"117","author":"Silva","year":"2011","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.blre.2022.100965_bb0340","doi-asserted-by":"crossref","first-page":"12862","DOI":"10.18632\/oncotarget.3868","article-title":"New dimension in therapeutic targeting of BCL-2 family proteins","volume":"6","author":"Besbes","year":"2015","journal-title":"Oncotarget"},{"issue":"25","key":"10.1016\/j.blre.2022.100965_bb0345","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2011.37.0981","article-title":"Targeting the B-cell lymphoma\/leukaemia 2 family in cancer","volume":"30","author":"Davids","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.blre.2022.100965_bb0350","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.blre.2022.100965_bb0355","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1158\/1078-0432.CCR-17-3004","article-title":"Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas","volume":"24","author":"Pham","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.blre.2022.100965_bb0360","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1182\/blood.V96.9.2951","article-title":"Mechanisms of HIV-associated lymphocyte apoptosis","volume":"96","author":"Badley","year":"2000","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2022.100965_bb0365","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00107-19","article-title":"The Role of the BCL-2 Family of Proteins in HIV-1 Pathogenesis and Persistence","volume":"33","author":"Chandrasekar","year":"2019","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"10.1016\/j.blre.2022.100965_bb0370","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1172\/JCI132374","article-title":"BCL-2 antagonism sensitizes cytotoxic t cell-resistant hiv reservoirs to elimination ex vivo","volume":"130","author":"Ren","year":"2020","journal-title":"J Clin Invest"},{"issue":"91","key":"10.1016\/j.blre.2022.100965_bb0375","first-page":"12","article-title":"Maintenance of the HIV Reservoir Is Antagonized by Selective BCL2 Inhibition","volume":"12","author":"Cummins","year":"2017","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.blre.2022.100965_bb0380","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095219","article-title":"Activation of the PI3K\/mTOR\/AKT pathway and survival in solid tumors: systematic review and meta-analysis","volume":"9","author":"Ocana","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.blre.2022.100965_bb0385","doi-asserted-by":"crossref","first-page":"14304","DOI":"10.3390\/molecules190914304","article-title":"Inhibition of the PI3K\/Akt\/mTOR Signalling Pathway in Diffuse Large B-Cell Lymphoma: Current Knowledge and Clinical Significance","volume":"19","author":"Majchrzak","year":"2014","journal-title":"Molecules"},{"issue":"21","key":"10.1016\/j.blre.2022.100965_bb0390","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.4161\/cc.26575","article-title":"PI3K\/AKT addiction in subsets of diffuse large B-cell lymphoma","volume":"12","author":"Pfeifer","year":"2013","journal-title":"Cell Cycle"},{"issue":"5","key":"10.1016\/j.blre.2022.100965_bb0395","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/s41375-021-01132-5","article-title":"Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukaemia","volume":"35","author":"Ge","year":"2021","journal-title":"Leukaemia"},{"issue":"0390-6078","key":"10.1016\/j.blre.2022.100965_bb0400","first-page":"1","article-title":"Phase I\/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas","volume":"106","author":"Major","year":"2021","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.blre.2022.100965_bb0405","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.1074\/jbc.M807898200","article-title":"Suberoylanilide Hydroxamic Acid Reactivates HIV from Latently Infected Cells","volume":"284","author":"Contreras","year":"2009","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.blre.2022.100965_bb0410","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.chom.2016.11.001","article-title":"The mTOR Complex Controls HIV Latency","volume":"20","author":"Besnard","year":"2016","journal-title":"Cell Host Microbe"},{"issue":"15\u201316","key":"10.1016\/j.blre.2022.100965_bb0415","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.drudis.2011.05.008","article-title":"mTOR as a multifunctional therapeutic target in HIV infection","volume":"16","author":"Nicoletti","year":"2011","journal-title":"Drug Discov Today"},{"issue":"16","key":"10.1016\/j.blre.2022.100965_bb0420","doi-asserted-by":"crossref","first-page":"5808","DOI":"10.1074\/jbc.RA118.002353","article-title":"Induction of autophagy by PI3K\/MTOR and PI3K\/MTOR\/BRD4 inhibitors suppresses HIV-1 replication","volume":"293","author":"Campbell","year":"2018","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.blre.2022.100965_bb0425","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1534-5807(02)00376-3","article-title":"The JAK\/STAT Pathway in Model Organisms: Emerging Roles in Cell Movement","volume":"3","author":"Hou","year":"2002","journal-title":"Dev Cell"},{"issue":"2","key":"10.1016\/j.blre.2022.100965_bb0430","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in Immunity, Immunodeficiency, and Cancer","volume":"368","author":"Oshea","year":"2013","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.blre.2022.100965_bb0435","doi-asserted-by":"crossref","first-page":"10151","DOI":"10.1073\/pnas.0604042103","article-title":"STAT3: A multifaceted oncogene","volume":"103","author":"Levy","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.blre.2022.100965_bb0440","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1182\/blood-2007-09-111948","article-title":"Cooperative signalling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma","volume":"111","author":"Lam","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2022.100965_bb0445","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1182\/blood-2011-10-388538","article-title":"Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation","volume":"119","author":"Gupta","year":"2012","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.blre.2022.100965_bb0450","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood-2018-03-841015","article-title":"B-cell receptor-mediated NFATc1 activation induces IL-10\/STAT3\/PD-L1 signalling in diffuse large B-cell lymphoma","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2022.100965_bb0455","series-title":"A novel silicone derivative of natural osalmid (DCZ0858) induces apoptosis and cell cycle arrest in diffuse large B-cell lymphoma via the JAK2\/STAT3 pathway","author":"Lu","year":"2020"},{"issue":"3","key":"10.1016\/j.blre.2022.100965_bb0460","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.bbrc.2010.03.092","article-title":"Conditional deletion of Stat3 promotes neurogenesis and inhibits astrogliogenesis in neural stem cells","volume":"394","author":"Cao","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"14\u201315","key":"10.1016\/j.blre.2022.100965_bb0465","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.micinf.2007.09.008","article-title":"Integration of HIV-1 caused STAT3-associated B cell lymphoma in an AIDS patient","volume":"9","author":"Katano","year":"2007","journal-title":"Microbes Infect"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X2200039X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X2200039X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:27:32Z","timestamp":1759436852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X2200039X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":92,"alternative-id":["S0268960X2200039X"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2022.100965","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"One arrow for two targets: potential co-treatment regimens for lymphoma and HIV","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2022.100965","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100965"}}